Radioiodine uptake in thyroid cancer patients after diagnostic application of low-dose 131I
The aim of this study was to investigate the influence of the diagnostic administration of 74 MBq I on subsequent uptake of therapeutic radioiodine in thyroid cancer patients. Retention measurements were performed using a whole-body counter in 24 patients 6 weeks after total thyroidectomy. Profile s...
Gespeichert in:
| Veröffentlicht in: | Nuclear medicine communications 1996-10, Vol.17 (10), p.839-839 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 839 |
|---|---|
| container_issue | 10 |
| container_start_page | 839 |
| container_title | Nuclear medicine communications |
| container_volume | 17 |
| creator | HUIČ, D MEDVEDEC, M DODIG, D POPOVIČ, S IVANČEVIČ, D PAVLINOVIČ, Ž ŽUVIČ, M |
| description | The aim of this study was to investigate the influence of the diagnostic administration of 74 MBq I on subsequent uptake of therapeutic radioiodine in thyroid cancer patients. Retention measurements were performed using a whole-body counter in 24 patients 6 weeks after total thyroidectomy. Profile scans were performed 2, 24, 48 and 72 h after the administration of the diagnostic dose and 72 h after the administration of the ablation-therapeutic dose (4.4 GBq). The mean (±S.D.) effective half-life of the diagnostic dose in thyroid remnants was 40.3 ± 23.0 h. The uptake in the thyroid remnants of the subsequent ablation dose 72 h after administration was 30.4 ± 19.8% of that predicted from the diagnostic study. The greater reduction in uptake was associated with the longer half-life of iodine and higher uptake in the thyroid remnants at 24 h, with a longer interval between surgery and administration of the diagnostic dose and a shorter period between administration of the diagnostic and ablation doses. Our results show that a diagnostic dose of 74 MBq I markedly reduces thyroid uptake of an ablation dose of I. This should be taken into account during radiation dose planning whenever a quantitative dosimetric study is to be performed. |
| doi_str_mv | 10.1097/00006231-199610000-00003 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78593606</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78593606</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2313-a840e9e0e6a1ee4b8f7e7d793157d0ba6d5254638d6927e9857c709c785016a33</originalsourceid><addsrcrecordid>eNp1kc9vFCEUgInR1LX1TzDhYLyNwjDDj6NprDZpYtLUUw_kLbxxsewwwkw2_e9l3HVvcoA83vd48EEI5ewjZ0Z9YnXIVvCGGyP5GjXrJF6QDe-UaHrZ6pdkw3gnGiGFfE3elPKrElpIdUEutOm5YWJDHu_BhxSSDyPSZZrhCWkY6bx7zil46mB0mOkEc8BxLhSGuYY-wM8xlTk4CtMUg6vpNNI00JgOjU8FKRf89oq8GiAWfHtaL8mPmy8P19-au-9fb68_3zWuvkA0oDuGBhlK4IjdVg8KlVdG8F55tgXp-7bvpNBemlah0b1yihmndM-4BCEuyYfjuVNOvxcss92H4jBGGDEtxVbQCMlkBfURdDmVknGwUw57yM-WM7t6tf-82rPXv1trj3enHst2j_5ceBJZ8-9PeSgO4pCruFDOWNtpJeV6g-6IHVKsJstTXA6Y7Q4hzjv7v18VfwDOaI5n</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78593606</pqid></control><display><type>article</type><title>Radioiodine uptake in thyroid cancer patients after diagnostic application of low-dose 131I</title><source>Journals@Ovid Ovid Autoload</source><source>MEDLINE</source><creator>HUIČ, D ; MEDVEDEC, M ; DODIG, D ; POPOVIČ, S ; IVANČEVIČ, D ; PAVLINOVIČ, Ž ; ŽUVIČ, M</creator><creatorcontrib>HUIČ, D ; MEDVEDEC, M ; DODIG, D ; POPOVIČ, S ; IVANČEVIČ, D ; PAVLINOVIČ, Ž ; ŽUVIČ, M</creatorcontrib><description>The aim of this study was to investigate the influence of the diagnostic administration of 74 MBq I on subsequent uptake of therapeutic radioiodine in thyroid cancer patients. Retention measurements were performed using a whole-body counter in 24 patients 6 weeks after total thyroidectomy. Profile scans were performed 2, 24, 48 and 72 h after the administration of the diagnostic dose and 72 h after the administration of the ablation-therapeutic dose (4.4 GBq). The mean (±S.D.) effective half-life of the diagnostic dose in thyroid remnants was 40.3 ± 23.0 h. The uptake in the thyroid remnants of the subsequent ablation dose 72 h after administration was 30.4 ± 19.8% of that predicted from the diagnostic study. The greater reduction in uptake was associated with the longer half-life of iodine and higher uptake in the thyroid remnants at 24 h, with a longer interval between surgery and administration of the diagnostic dose and a shorter period between administration of the diagnostic and ablation doses. Our results show that a diagnostic dose of 74 MBq I markedly reduces thyroid uptake of an ablation dose of I. This should be taken into account during radiation dose planning whenever a quantitative dosimetric study is to be performed.</description><identifier>ISSN: 0143-3636</identifier><identifier>EISSN: 1473-5628</identifier><identifier>DOI: 10.1097/00006231-199610000-00003</identifier><identifier>PMID: 8951903</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott-Raven Publishers</publisher><subject>Biological and medical sciences ; Endocrinopathies ; Female ; Half-Life ; Humans ; Iodine Radioisotopes - pharmacokinetics ; Iodine Radioisotopes - therapeutic use ; Male ; Malignant tumors ; Medical sciences ; Middle Aged ; Radionuclide Imaging ; Thyroid Gland - diagnostic imaging ; Thyroid Neoplasms - diagnostic imaging ; Thyroid Neoplasms - radiotherapy ; Thyroid Neoplasms - surgery ; Thyroid. Thyroid axis (diseases) ; Thyroidectomy ; Tissue Distribution</subject><ispartof>Nuclear medicine communications, 1996-10, Vol.17 (10), p.839-839</ispartof><rights>Lippincott-Raven Publishers.</rights><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2313-a840e9e0e6a1ee4b8f7e7d793157d0ba6d5254638d6927e9857c709c785016a33</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2487666$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8951903$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HUIČ, D</creatorcontrib><creatorcontrib>MEDVEDEC, M</creatorcontrib><creatorcontrib>DODIG, D</creatorcontrib><creatorcontrib>POPOVIČ, S</creatorcontrib><creatorcontrib>IVANČEVIČ, D</creatorcontrib><creatorcontrib>PAVLINOVIČ, Ž</creatorcontrib><creatorcontrib>ŽUVIČ, M</creatorcontrib><title>Radioiodine uptake in thyroid cancer patients after diagnostic application of low-dose 131I</title><title>Nuclear medicine communications</title><addtitle>Nucl Med Commun</addtitle><description>The aim of this study was to investigate the influence of the diagnostic administration of 74 MBq I on subsequent uptake of therapeutic radioiodine in thyroid cancer patients. Retention measurements were performed using a whole-body counter in 24 patients 6 weeks after total thyroidectomy. Profile scans were performed 2, 24, 48 and 72 h after the administration of the diagnostic dose and 72 h after the administration of the ablation-therapeutic dose (4.4 GBq). The mean (±S.D.) effective half-life of the diagnostic dose in thyroid remnants was 40.3 ± 23.0 h. The uptake in the thyroid remnants of the subsequent ablation dose 72 h after administration was 30.4 ± 19.8% of that predicted from the diagnostic study. The greater reduction in uptake was associated with the longer half-life of iodine and higher uptake in the thyroid remnants at 24 h, with a longer interval between surgery and administration of the diagnostic dose and a shorter period between administration of the diagnostic and ablation doses. Our results show that a diagnostic dose of 74 MBq I markedly reduces thyroid uptake of an ablation dose of I. This should be taken into account during radiation dose planning whenever a quantitative dosimetric study is to be performed.</description><subject>Biological and medical sciences</subject><subject>Endocrinopathies</subject><subject>Female</subject><subject>Half-Life</subject><subject>Humans</subject><subject>Iodine Radioisotopes - pharmacokinetics</subject><subject>Iodine Radioisotopes - therapeutic use</subject><subject>Male</subject><subject>Malignant tumors</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Radionuclide Imaging</subject><subject>Thyroid Gland - diagnostic imaging</subject><subject>Thyroid Neoplasms - diagnostic imaging</subject><subject>Thyroid Neoplasms - radiotherapy</subject><subject>Thyroid Neoplasms - surgery</subject><subject>Thyroid. Thyroid axis (diseases)</subject><subject>Thyroidectomy</subject><subject>Tissue Distribution</subject><issn>0143-3636</issn><issn>1473-5628</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc9vFCEUgInR1LX1TzDhYLyNwjDDj6NprDZpYtLUUw_kLbxxsewwwkw2_e9l3HVvcoA83vd48EEI5ewjZ0Z9YnXIVvCGGyP5GjXrJF6QDe-UaHrZ6pdkw3gnGiGFfE3elPKrElpIdUEutOm5YWJDHu_BhxSSDyPSZZrhCWkY6bx7zil46mB0mOkEc8BxLhSGuYY-wM8xlTk4CtMUg6vpNNI00JgOjU8FKRf89oq8GiAWfHtaL8mPmy8P19-au-9fb68_3zWuvkA0oDuGBhlK4IjdVg8KlVdG8F55tgXp-7bvpNBemlah0b1yihmndM-4BCEuyYfjuVNOvxcss92H4jBGGDEtxVbQCMlkBfURdDmVknGwUw57yM-WM7t6tf-82rPXv1trj3enHst2j_5ceBJZ8-9PeSgO4pCruFDOWNtpJeV6g-6IHVKsJstTXA6Y7Q4hzjv7v18VfwDOaI5n</recordid><startdate>199610</startdate><enddate>199610</enddate><creator>HUIČ, D</creator><creator>MEDVEDEC, M</creator><creator>DODIG, D</creator><creator>POPOVIČ, S</creator><creator>IVANČEVIČ, D</creator><creator>PAVLINOVIČ, Ž</creator><creator>ŽUVIČ, M</creator><general>Lippincott-Raven Publishers</general><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199610</creationdate><title>Radioiodine uptake in thyroid cancer patients after diagnostic application of low-dose 131I</title><author>HUIČ, D ; MEDVEDEC, M ; DODIG, D ; POPOVIČ, S ; IVANČEVIČ, D ; PAVLINOVIČ, Ž ; ŽUVIČ, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2313-a840e9e0e6a1ee4b8f7e7d793157d0ba6d5254638d6927e9857c709c785016a33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Biological and medical sciences</topic><topic>Endocrinopathies</topic><topic>Female</topic><topic>Half-Life</topic><topic>Humans</topic><topic>Iodine Radioisotopes - pharmacokinetics</topic><topic>Iodine Radioisotopes - therapeutic use</topic><topic>Male</topic><topic>Malignant tumors</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Radionuclide Imaging</topic><topic>Thyroid Gland - diagnostic imaging</topic><topic>Thyroid Neoplasms - diagnostic imaging</topic><topic>Thyroid Neoplasms - radiotherapy</topic><topic>Thyroid Neoplasms - surgery</topic><topic>Thyroid. Thyroid axis (diseases)</topic><topic>Thyroidectomy</topic><topic>Tissue Distribution</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HUIČ, D</creatorcontrib><creatorcontrib>MEDVEDEC, M</creatorcontrib><creatorcontrib>DODIG, D</creatorcontrib><creatorcontrib>POPOVIČ, S</creatorcontrib><creatorcontrib>IVANČEVIČ, D</creatorcontrib><creatorcontrib>PAVLINOVIČ, Ž</creatorcontrib><creatorcontrib>ŽUVIČ, M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Nuclear medicine communications</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HUIČ, D</au><au>MEDVEDEC, M</au><au>DODIG, D</au><au>POPOVIČ, S</au><au>IVANČEVIČ, D</au><au>PAVLINOVIČ, Ž</au><au>ŽUVIČ, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Radioiodine uptake in thyroid cancer patients after diagnostic application of low-dose 131I</atitle><jtitle>Nuclear medicine communications</jtitle><addtitle>Nucl Med Commun</addtitle><date>1996-10</date><risdate>1996</risdate><volume>17</volume><issue>10</issue><spage>839</spage><epage>839</epage><pages>839-839</pages><issn>0143-3636</issn><eissn>1473-5628</eissn><abstract>The aim of this study was to investigate the influence of the diagnostic administration of 74 MBq I on subsequent uptake of therapeutic radioiodine in thyroid cancer patients. Retention measurements were performed using a whole-body counter in 24 patients 6 weeks after total thyroidectomy. Profile scans were performed 2, 24, 48 and 72 h after the administration of the diagnostic dose and 72 h after the administration of the ablation-therapeutic dose (4.4 GBq). The mean (±S.D.) effective half-life of the diagnostic dose in thyroid remnants was 40.3 ± 23.0 h. The uptake in the thyroid remnants of the subsequent ablation dose 72 h after administration was 30.4 ± 19.8% of that predicted from the diagnostic study. The greater reduction in uptake was associated with the longer half-life of iodine and higher uptake in the thyroid remnants at 24 h, with a longer interval between surgery and administration of the diagnostic dose and a shorter period between administration of the diagnostic and ablation doses. Our results show that a diagnostic dose of 74 MBq I markedly reduces thyroid uptake of an ablation dose of I. This should be taken into account during radiation dose planning whenever a quantitative dosimetric study is to be performed.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott-Raven Publishers</pub><pmid>8951903</pmid><doi>10.1097/00006231-199610000-00003</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0143-3636 |
| ispartof | Nuclear medicine communications, 1996-10, Vol.17 (10), p.839-839 |
| issn | 0143-3636 1473-5628 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78593606 |
| source | Journals@Ovid Ovid Autoload; MEDLINE |
| subjects | Biological and medical sciences Endocrinopathies Female Half-Life Humans Iodine Radioisotopes - pharmacokinetics Iodine Radioisotopes - therapeutic use Male Malignant tumors Medical sciences Middle Aged Radionuclide Imaging Thyroid Gland - diagnostic imaging Thyroid Neoplasms - diagnostic imaging Thyroid Neoplasms - radiotherapy Thyroid Neoplasms - surgery Thyroid. Thyroid axis (diseases) Thyroidectomy Tissue Distribution |
| title | Radioiodine uptake in thyroid cancer patients after diagnostic application of low-dose 131I |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T20%3A57%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Radioiodine%20uptake%20in%20thyroid%20cancer%20patients%20after%20diagnostic%20application%20of%20low-dose%20131I&rft.jtitle=Nuclear%20medicine%20communications&rft.au=HUI%C4%8C,%20D&rft.date=1996-10&rft.volume=17&rft.issue=10&rft.spage=839&rft.epage=839&rft.pages=839-839&rft.issn=0143-3636&rft.eissn=1473-5628&rft_id=info:doi/10.1097/00006231-199610000-00003&rft_dat=%3Cproquest_cross%3E78593606%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78593606&rft_id=info:pmid/8951903&rfr_iscdi=true |